|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1 An Open Label, Randomized, Single Dose, 2-sequence, 2-period, Cross-over Phase 1 Study to Evaluate the Safety and Pharmacokinetics of AJU-C714 Compared to C714R in Healthy Adult Volunteers
To evaluate the safety and pharmacokinetic characteristics of AJU-C714 and C714R in healthy adults
An Open Label, Randomized, Single Dose, 2-sequence, 2-period, Cross-over Phase 1 Study to Evaluate Bioequivalence of AJU-C711 Compared to C711R in Healthy Adult Volunteers
To evaluate the safety and pharmacokinetic characteristics of AJU-C711 in healthy adults
A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase 4 Study to Evaluate the Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
This study is planned to Evaluate the Efficacy and Safety of OM-89 in Patients with Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
100 Clinical Results associated with Aju Pharm Co. Ltd.
0 Patents (Medical) associated with Aju Pharm Co. Ltd.
100 Deals associated with Aju Pharm Co. Ltd.
100 Translational Medicine associated with Aju Pharm Co. Ltd.